These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 7665549)

  • 21. [Atypical antipsychotic drugs].
    Kahn RS
    Ned Tijdschr Geneeskd; 2000 Aug; 144(34):1627-30. PubMed ID: 10972052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors.
    Harrison PJ
    Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896
    [No Abstract]   [Full Text] [Related]  

  • 23. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients.
    Keshavan MS; Prasad KM; Montrose DM; Miewald JM; Kupfer DJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):703-5. PubMed ID: 18004141
    [No Abstract]   [Full Text] [Related]  

  • 25. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 3():16-21. PubMed ID: 10724129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of psychosis: 30 years of progress.
    De Oliveira IR; Juruena MF
    J Clin Pharm Ther; 2006 Dec; 31(6):523-34. PubMed ID: 17176358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting cognition in schizophrenia research: from etiology to treatment.
    Goldberg TE; Gomar JJ
    Am J Psychiatry; 2009 Jun; 166(6):631-4. PubMed ID: 19487396
    [No Abstract]   [Full Text] [Related]  

  • 28. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication.
    Hong WW; Rak IW; Ciuryla VT; Wilson AM; Kylstra JW; Meltzer HY; Carpenter WT; Lehman A; Arvanitis LA
    Schizophr Res; 1998 Jun; 32(1):51-8. PubMed ID: 9690334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differing tolerability profiles among atypical antipsychotics.
    Hellewell JS; Haddad PM
    Am J Psychiatry; 2001 Mar; 158(3):501-2. PubMed ID: 11230007
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder.
    Prieto E; Micó JA; Meana JJ; Majadas S
    Actas Esp Psiquiatr; 2010; 38(1):22-32. PubMed ID: 20931407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia.
    Deutch AY; Moghaddam B; Innis RB; Krystal JH; Aghajanian GK; Bunney BS; Charney DS
    Schizophr Res; 1991; 4(2):121-56. PubMed ID: 1674882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia.
    Lynch J; Morrison J; Graves N; Meddis D; Drummond MF; Hellewell JS
    Eur Psychiatry; 2001 Aug; 16(5):307-12. PubMed ID: 11514134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful use of quetiapine in two successive pregnancies.
    Grover S; Madan R
    J Neuropsychiatry Clin Neurosci; 2012; 24(1):E38. PubMed ID: 22450643
    [No Abstract]   [Full Text] [Related]  

  • 35. [Seroquel in a resistant schizophrenic with negative and positive symptoms].
    Reznik I; Benatov R; Sirota P
    Harefuah; 1996 May; 130(10):675-7, 727. PubMed ID: 8794656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine in schizophrenia: onset of action within the first week of treatment.
    Small JG; Kolar MC; Kellams JJ
    Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does loxapine have "atypical" properties? Clinical evidence.
    Glazer WM
    J Clin Psychiatry; 1999; 60 Suppl 10():42-6. PubMed ID: 10340686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful outcome using quetiapine in a case of treatment-resistant schizophrenia with assaultive behavior.
    Brooks JO
    Schizophr Res; 2001 May; 50(1-2):133-4. PubMed ID: 11378322
    [No Abstract]   [Full Text] [Related]  

  • 39. Quetiapine: a review of its use in the treatment of bipolar depression.
    Keating GM; Robinson DM
    Drugs; 2007; 67(7):1077-95. PubMed ID: 17488148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?
    Meltzer HY
    Int J Neuropsychopharmacol; 2005 Jun; 8(2):153-6. PubMed ID: 15780147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.